BACKGROUND
Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...
F. Pecci, Xinan Wang, Valentina Santo et al.· Journal of Thoracic Oncology· 0 citations
KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.
E. Garbo, P. Scaparone, Hui Jing Hoe et al.· The Journal of the National...· 0 citations
An open-source Bayesian inference tool that determines the multiplicity and copy number of driver mutations from tumor sequencing datasets is presented, an open-source Bayesian inference tool that determines the multiplicity and copy number of driver mutations from tumor sequencing datasets.
N. Calonaci, E. Krasniqi, D. Čolić et al.· Nature Genetics· 0 citations
RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.
F. Facchinetti, L. Friboulet, L. Liao et al.· Annals of Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
